<p>*NA = not applicable</p><p>** Administered dose / planned dose according to the protocol per cohort (%)</p><p>*** Median administered dose / planned dose according to the protocol per patient per cohort (%)</p><p>Treatment exposures, number of treatment cycles and median delivered dose of the study drugs.</p
As all anti-cancer drugs are of narrow therapeutic window so dose individualization is required to b...
<p>Data are <i>n</i> (percent of regimen). Categories differentiate full DOT (here meaning entire co...
<p>n: number of resistance tests (first test/patient per year) presenting with mutations associated ...
<p>Cohort I: Percent of Targeted Dose (relative to targeted dose at start of treatment) for patients...
<p>Note: In each scenario, the first row of number in parentheses corresponds to the dose selection ...
a<p>Treatment duration = [(the study treatment end date)−(the first study drug start date)+1]/7.</p>...
<p>Data are ECP (95% CI). See <a href="http://www.plosmedicine.org/article/info:doi/10.1371/journal....
<p>Cohort II: Percent of Targeted Dose (relative to targeted dose at start of treatment)for patients...
Proportion of the study participants with respective understanding level of dosage regimen instructi...
The number of monitor units (MU), beam-on time (BOT), and mean dose rate (MDR) for treatment plans c...
For the two models created, 42 patients we used a training cohort of 30 patients with 12 subjects as...
<p>Treatments administered by each study and respective study characteristics for included efficacy ...
textabstractBackground: Dose banding is a recently suggested dosing method that uses predefined rang...
Percentage of trials with the estimated MTD inside the optimal MTD interval and average percentage o...
<p>Descriptive statistics of the adjuvant chemotherapy and molecular targeted agents employed in eac...
As all anti-cancer drugs are of narrow therapeutic window so dose individualization is required to b...
<p>Data are <i>n</i> (percent of regimen). Categories differentiate full DOT (here meaning entire co...
<p>n: number of resistance tests (first test/patient per year) presenting with mutations associated ...
<p>Cohort I: Percent of Targeted Dose (relative to targeted dose at start of treatment) for patients...
<p>Note: In each scenario, the first row of number in parentheses corresponds to the dose selection ...
a<p>Treatment duration = [(the study treatment end date)−(the first study drug start date)+1]/7.</p>...
<p>Data are ECP (95% CI). See <a href="http://www.plosmedicine.org/article/info:doi/10.1371/journal....
<p>Cohort II: Percent of Targeted Dose (relative to targeted dose at start of treatment)for patients...
Proportion of the study participants with respective understanding level of dosage regimen instructi...
The number of monitor units (MU), beam-on time (BOT), and mean dose rate (MDR) for treatment plans c...
For the two models created, 42 patients we used a training cohort of 30 patients with 12 subjects as...
<p>Treatments administered by each study and respective study characteristics for included efficacy ...
textabstractBackground: Dose banding is a recently suggested dosing method that uses predefined rang...
Percentage of trials with the estimated MTD inside the optimal MTD interval and average percentage o...
<p>Descriptive statistics of the adjuvant chemotherapy and molecular targeted agents employed in eac...
As all anti-cancer drugs are of narrow therapeutic window so dose individualization is required to b...
<p>Data are <i>n</i> (percent of regimen). Categories differentiate full DOT (here meaning entire co...
<p>n: number of resistance tests (first test/patient per year) presenting with mutations associated ...